ATE509632T1 - Behandlung von entzündlicher darmerkrankung - Google Patents

Behandlung von entzündlicher darmerkrankung

Info

Publication number
ATE509632T1
ATE509632T1 AT03750165T AT03750165T ATE509632T1 AT E509632 T1 ATE509632 T1 AT E509632T1 AT 03750165 T AT03750165 T AT 03750165T AT 03750165 T AT03750165 T AT 03750165T AT E509632 T1 ATE509632 T1 AT E509632T1
Authority
AT
Austria
Prior art keywords
treatment
inflammatory bowel
bowel disease
methods
compounds
Prior art date
Application number
AT03750165T
Other languages
English (en)
Inventor
Trent Woodruff
Stephen Taylor
David Fairlie
Original Assignee
Promics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002952084A external-priority patent/AU2002952084A0/en
Priority claimed from AU2003902452A external-priority patent/AU2003902452A0/en
Application filed by Promics Pty Ltd filed Critical Promics Pty Ltd
Application granted granted Critical
Publication of ATE509632T1 publication Critical patent/ATE509632T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03750165T 2002-10-16 2003-10-15 Behandlung von entzündlicher darmerkrankung ATE509632T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952084A AU2002952084A0 (en) 2002-10-16 2002-10-16 Treatment of inflammatory bowel disease
AU2003902452A AU2003902452A0 (en) 2003-05-20 2003-05-20 Treatment of inflammatory bowel disease
PCT/AU2003/001365 WO2004035078A1 (en) 2002-10-16 2003-10-15 Treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
ATE509632T1 true ATE509632T1 (de) 2011-06-15

Family

ID=32108554

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03750165T ATE509632T1 (de) 2002-10-16 2003-10-15 Behandlung von entzündlicher darmerkrankung

Country Status (6)

Country Link
US (2) US7410945B2 (de)
EP (1) EP1558277B1 (de)
JP (1) JP4818726B2 (de)
AT (1) ATE509632T1 (de)
CA (1) CA2542507C (de)
WO (1) WO2004035078A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
ATE509632T1 (de) * 2002-10-16 2011-06-15 Promics Pty Ltd Behandlung von entzündlicher darmerkrankung
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
US7885748B2 (en) * 2006-09-13 2011-02-08 Gm Global Technology Operations, Inc. Virtual accelerometer
RU2465272C2 (ru) 2007-09-10 2012-10-27 КалсиМедика, Инк. Соединения, моделирующие внутриклеточный кальций
WO2009052489A2 (en) * 2007-10-19 2009-04-23 Alba Therapeutics Corporation Novel inhibitors of mammalian tight junction opening
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CA2734500A1 (en) * 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US8524763B2 (en) * 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
US8618307B2 (en) 2009-09-16 2013-12-31 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2019075319A1 (en) * 2017-10-12 2019-04-18 Board Of Regents, The University Of Texas System COMPOSITIONS AND METHODS FOR TREATING PAIN IN WOMEN
CN116115582B (zh) * 2022-11-10 2024-04-16 重庆大学 前药封装的工程化益生菌及其制备方法与应用
WO2026030184A1 (en) * 2024-08-01 2026-02-05 Merck Sharp & Dohme Llc Long-acting cyclic peptides for inhibiting tnf receptor 1 activity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5707622A (en) * 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
JPH11507215A (ja) * 1995-06-05 1999-06-29 ノバルティス・アクチエンゲゼルシャフト アゴニスト活性を実質的にもたないＣ５ａ受容体アンタゴニストおよび製造方法
SE9701219D0 (sv) * 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
US6611377B1 (en) * 2000-07-10 2003-08-26 Intel Corporation Micromechanical diffraction phase grating
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
ATE509632T1 (de) * 2002-10-16 2011-06-15 Promics Pty Ltd Behandlung von entzündlicher darmerkrankung
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
AU2003902586A0 (en) * 2003-05-26 2003-06-12 The University Of Queensland Treatment of burns
US7910945B2 (en) * 2006-06-30 2011-03-22 Cree, Inc. Nickel tin bonding system with barrier layer for semiconductor wafers and devices

Also Published As

Publication number Publication date
CA2542507C (en) 2013-04-16
EP1558277A1 (de) 2005-08-03
US20090004264A1 (en) 2009-01-01
JP2006505621A (ja) 2006-02-16
EP1558277B1 (de) 2011-05-18
US20060135411A1 (en) 2006-06-22
CA2542507A1 (en) 2004-04-29
JP4818726B2 (ja) 2011-11-16
WO2004035078A1 (en) 2004-04-29
US7410945B2 (en) 2008-08-12
EP1558277A4 (de) 2009-07-29

Similar Documents

Publication Publication Date Title
ES2340179T3 (es) Antagonistas de urea del receptor p2y1 utiles en el tratamiento de afecciones tromboticas.
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
HUP0203677A2 (hu) Muszkarin receptor antagonista aktivitással rendelkező karbamid vegyületek
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
EP1605936A4 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
EP1558277A4 (de) BEHANDLUNG VON ENTZüNDLICHER DARMERKRANKUNG
CY1109487T1 (el) Ανταγωνιστες τυπου ουριας του υποδοχεα p2y1 χρησιμοι στην αγωγη θρομβωτικων καταστασεων
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
ATE535514T1 (de) Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
EP1017713A4 (de) ZYKLISCHE AGONISTEN UND ANTAGONISTEN DER C5a REZEPTOREN SOWIE G-PROTEIN GEKOPPELTEN REZEPTOREN
ATE509019T1 (de) Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
PL1933869T3 (pl) Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu
EP1951251A4 (de) Spirohydantoin-aryl-cgrp-rezeptorantagonisten
DE60314896D1 (de) 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
DE602006020871D1 (de) Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
SG151283A1 (en) Treatment of neurological conditions using complement c5a receptor modulators
EP1856100A4 (de) Cgrp-rezeptorantagonisten
WO2008120263A3 (en) Prokineticins receptors antagonists, derivatives and uses thereof
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
ATE454153T1 (de) 5-ht4 antagonisten zur behandlung von herzversagen
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
NO20076387L (no) Anvendelse av IL-18BP isoformer til behandling og/eller forhindring av neurologiske inflammatoriske sykdommer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties